919 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
TEVA Teva Pharmaceutical Industries Limited $23.43 $23.86B N/A
Article Searches
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know http://www.zacks.com/stock/news/429353/teva-pharmaceutical-industries-ltd-teva-stock-sinks-as-market-gains-what-you-should-know?cid=CS-ZC-FT-429353 Jun 13, 2019 - Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.62 in the latest trading session, marking a -1.03% move from the prior day.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know http://www.zacks.com/stock/news/432456/teva-pharmaceutical-industries-ltd-teva-stock-sinks-as-market-gains-what-you-should-know?cid=CS-ZC-FT-432456 Jun 20, 2019 - Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.12 in the latest trading session, marking a -0.73% move from the prior day.
J&J to Pay $572M in Opioid Case; Plus Case-Shiller Home Price Read http://www.zacks.com/stock/news/491012/jj-to-pay-%24572m-in-opioid-case-plus-case-shiller-home-price-read?cid=CS-ZC-FT-ahead_of_wall_street-491012 Aug 27, 2019 - Johnson & Johnson (JNJ) now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use.
Novartis Announces Positive Long-Term Data on Migraine Drug http://www.zacks.com/stock/news/509529/novartis-announces-positive-long-term-data-on-migraine-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-509529 Sep 09, 2019 - Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know http://www.zacks.com/stock/news/521635/teva-pharmaceutical-industries-ltd-teva-gains-as-market-dips-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-521635 Sep 16, 2019 - Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $8.04, moving +1.26% from the previous trading session.
J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use http://www.zacks.com/stock/news/526368/jjs-prostate-cancer-drug-gets-fda-nod-for-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-526368 Sep 19, 2019 - J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.
Mallinckrodt's StrataGraft Tissue Phase III Data Positive http://www.zacks.com/stock/news/533490/mallinckrodts-stratagraft-tissue-phase-iii-data-positive?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-533490 Sep 24, 2019 - Mallinckrodt's (MNK) experimental StrataGraft regenerative tissue meets goals in a late-stage study for the treatment of burns.
AstraZeneca's Fasenra Gets FDA Nod for Self-Administration http://www.zacks.com/stock/news/552912/astrazenecas-fasenra-gets-fda-nod-for-self-administration?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-552912 Oct 07, 2019 - The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know http://www.zacks.com/stock/news/553574/teva-pharmaceutical-industries-ltd-teva-gains-as-market-dips-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-553574 Oct 07, 2019 - Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.98 in the latest trading session, marking a +0.14% move from the prior day.
J&J (JNJ) Beats on Q3 Earnings as Sales Rise, Ups 2019 View http://www.zacks.com/stock/news/565810/jj-jnj-beats-on-q3-earnings-as-sales-rise-ups-2019-view?cid=CS-ZC-FT-analyst_blog|earnings_article-565810 Oct 15, 2019 - J&J (JNJ) comes up with encouraging third-quarter 2019 results.

Pages: 1...86878889909192

<<<Page 91